About Sahsen Ventures
Sahsen Ventures is a venture capital firm founded in 2016. It is primarily based out of Seattle, United States. As of Oct 2024, Sahsen Ventures has invested in 96 companies. It primarily invests in Seed round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Seed round of Archon Bio Overall, Sahsen Ventures portfolio has seen 1 unicorn, 15 IPOs and 9 acquisitions including key companies like Recursion Pharmaceuticals, Science 37 and Desktop Metal. A lot of funds co-invest with Sahsen Ventures, with names like Madrona sharing a substantial percentage of its portfolio. Sahsen Ventures has team of 4 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 3 more
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Sahsen Ventures' List of Top Investments
Sahsen Ventures has a portfolio of 96 companies, one of which is a Unicorn. Their most notable investments are in Freedom Fund and Uterish.Their portfolio spans across United States, China, United Kingdom and 3 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 23 other sectors, across stages such as Seed, Series A and 3 more. Here is the list of top investments by Sahsen Ventures:AI-enabled drug discovery and development platform for novel therapeutics. It focuses on identifying new targets and designing optimized molecules. The platform utilizes biological and chemical datasets, machine learning models, and a supercomputer to accelerate the discovery of medicines. It aims to improve the speed and efficiency of drug development for conditions with high unmet needs, including cancers and rare diseases. The company also forms strategic partnerships to expand its impact on patients.
Key facts about Recursion Pharmaceuticals
- Founded Year: 2013
- Location: New York (United States)
- Annual Revenue: $58.8M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $452M
- Employee Count: 515 as on Jan 31, 2024
- Investors: HTIF, Square 1 Bank and 46 Others
- Latest Funding Round: Post IPO, Jul 12, 2023, $*****
- Highlight: Public
2. Science 37
Science 37 offers end-to-end clinical trial solutions for researchers. Metasite, a clinical trial operating model of the company uses a mobile platform to allow patients to participate in the trial. The company has developed products like Science 37 Metasite that is a site-based clinical trial data collection on virtual media. The platform allows researchers to use the tool for trial management, data collection, and communication. The tool digital transformation allows users to study trail designing concepts and assist in virtualization. The tool provided by the company gives recruitment tools, patient enrollment system and more.
Key facts about Science 37
- Founded Year: 2014
- Location: Los Angeles (United States)
- Annual Revenue: $70.1M as on Dec 31, 2022
- Stage: Acquired
- Total Funding till date: $106M
- Employee Count: 306 as on Sep 15, 2025
- Investors: Glynn Capital, Google Ventures and 12 Others
- Latest Funding Round: Series D, Aug 20, 2020, $*****
- Highlight: Acquired
3. Ant Group
Payment processing solution for consumers, small and micro businesses. Offers a wallet for services such as money transfers, bill payments, online or offline payments, and more. It enables businesses to accept online payments from customers via credit or debit cards or bank transfers. It also offers personal and corporate credit solutions.
Key facts about Ant Group
- Founded Year: 2004
- Location: Hangzhou (China)
- Valuation: $*****
- Stage: Series D
- Total Funding till date: $30.5B
- Employee Count: 10,414 as on Dec 02, 2025
- Investors: Kaplan Group Investments, Silver Lake and 37 Others
- Latest Funding Round: Series D, Feb 09, 2021, $*****
- Highlight: Editors' Pick
Manufacturer of metal-based desktop 3D printers. It offers metal-based 3D printers for the mass production of metal parts and prototypes and carbon fiber-based 3D printers to manufacture fiber-reinforced parts using composites. It also provides software to control and manage 3D printing and these printers. It caters to automotive, consumer goods, education, machine design, heavy industry, and manufacturing tooling sectors.
Key facts about Desktop Metal
- Founded Year: 2015
- Location: Burlington (United States)
- Annual Revenue: $190M as on Dec 31, 2023
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $438M
- Employee Count: 231 as on Oct 24, 2025
- Investors: Ford, Google Ventures and 35 Others
- Latest Funding Round: Post IPO, May 10, 2022, $*****
- Highlight: Acquired
Roivant Sciences is developing therapeutics in disease areas such as neurology, oncology, rare diseases, and endocrinology. Its CNS drug pipeline include Intepirdine, a selective 5-HT6 receptor antagonist for mild-to-moderate Alzheimer's disease (phase 3), dementia with Lewy bodies (DLB) (phase 3), gait and balance impairments in dementia (phase 2); Nelotanserin, agonist of the 5-HT2A receptor for visual hallucinations in Lewy body dementia (phase 2), REM behavior disorder (RBD) in DLB (phase 2/3); RVT-103 and RVT-104 for Alzheimer's disease (phase 1) and Lewy body dementia (phase 1). Other drugs in the pipeline include Relugolix for uterine fibroids (phase 3), endometriosis (phase 3) and prostate cancer (phase 3). It is also developing drugs for atopic dermatitis (phase 2), autism (phase 2), female infertility (phase 2) and Farber disease (phase 2).
Key facts about Roivant Sciences
- Founded Year: 2014
- Location: New York City (United States)
- Annual Revenue: $29.1M as on Mar 31, 2025
- Stage: Public
- Total Funding till date: $1.3B
- Employee Count: 662 as on Dec 31, 2021
- Investors: Viking Global Investors, RTW Investments and 7 Others
- Latest Funding Round: PE, Nov 13, 2018, $*****
- Highlight: Public
Sahsen Ventures' Year-on-Year Investment Trends
Sahsen Ventures has invested in 96 companies over the last 10 years, with an average of 2 new investments annually in the last 10 years. Its most recent first time investment was in Archon Bio and most recent follow-on round was in Outpace Bio.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 1 | 1 | 2 |
2023 | 2 | 0 | 2 |
2022 | 2 | 0 | 2 |
2021 | 3 | 0 | 3 |
2020 | 1 | 0 | 1 |
2019 | 3 | 1 | 4 |
2018 | 2 | 0 | 2 |
2017 | 2 | 0 | 2 |
Sahsen Ventures' Investments by Stage
Sahsen Ventures has made 10 investments in Seed stage with an average round size of $13M, 3 investments in Series A stage with an average round size of $35.4M, 2 investments in Series C stage with an average round size of $70M, 1 investment in Series B stage with an average round size of $89M and 1 investment in Series D stage with an average round size of $135M.Stage of entry | No. of Investments |
|---|---|
Seed | 10 |
Series A | 3 |
Series C | 2 |
Series B | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
Sahsen Ventures' Investments by Sector
Sahsen Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, Sustainability Tech and Chemicals and Materials Tech. Notably, it has invested in 52 Tech companies, 50 Enterprise (B2B) companies, 15 Software companies and at least 8 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 13 |
High Tech | 5 |
Enterprise Applications | 3 |
Sustainability Tech | 3 |
Chemicals and Materials Tech | 2 |
Others | 8 |
Note: We have considered here, only first round of investments
Sahsen Ventures' Investments by Geography
Sahsen Ventures has made most investments in United States (16), followed by Australia where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 16 |
Australia | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
Sahsen Ventures' recent investments
Sahsen Ventures has not made any investment in 2026 so far.Here are the most recent investments by Sahsen Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 30, 2024 | United States | Seed | 8965 | [+5] | |
Jul 17, 2024 | United States | Series B | 8992 | [+12] | |
Dec 19, 2023 | United States | Seed | 6505 | [+4] | |
Dec 14, 2023 | United States | Series C | 4982 | [+4] | |
Aug 15, 2022 | United States | Seed | 6716 | [+5] |
Unicorns in Sahsen Ventures' Portfolio
Sahsen Ventures has 1 unicorn in its portfolio - Illumio. The most recent unicorn in their portfolio is Illumio which became a unicorn in 2017, 8 years before Sahsen Ventures first invested in it.Here is a list of unicorns in Sahsen Ventures' portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
64 | Provider of breach containment and AI cloud detection and response | 2013 | Sunnyvale | Series F | wlfjmzm |
IPOs and Publicly Listed companies in Sahsen Ventures' Portfolio
15 of Sahsen Ventures' portfolio companies have become public. Azitra got listed on the American Stock Exchange (NYSEAMERICAN), in Jun 2023 at marketcap of $60.4M and HilleVax got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $538M.Here are Sahsen Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 16, 2023 | - | - | 6087 | |
Apr 29, 2022 | Sep 08, 2021 | Series D | 7463 | |
Oct 01, 2021 | - | - | 7003 | |
Jun 17, 2021 | 2018 | Seed | 1939 | |
Apr 16, 2021 | - | - | 2209 |
Acquired companies in Sahsen Ventures' Portfolio
9 companies from Sahsen Ventures' portfolio have been acquired. The most recent acquisition was Desktop Metal in Jul 2024 by Nano Dimension for $*****.Here are Sahsen Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 02, 2024 | - | - | 2453 | |
Feb 10, 2024 | - | - | 8951 | |
Jan 29, 2024 | - | - | 4359 | |
Dec 12, 2023 | - | - | 6143 | |
Mar 06, 2023 | - | - | 5529 |
Team profile of Sahsen Ventures
Sahsen Ventures has a team of 4 members including 4 Partners located in United States. Sahsen Ventures' team does not sit on the board of any company as of now.Here is a list of all team members in Sahsen Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Seattle | - | ||
Partner | Seattle | - | - | |
Partner | Seattle | - | - | |
Partner | Seattle | - | - |
Co-investors of Sahsen Ventures
Over the past 10 years, 116 investors have co-invested in Sahsen Ventures's portfolio companies. This includes funds and angels.
- Invested before Sahsen Ventures: National Science Foundation, Alzheimer's Drug Discovery and 16 others have invested in rounds before Sahsen Ventures. There are 2 companies where National Science Foundation has invested before Sahsen Ventures and 1 company where Alzheimer's Drug Discovery has invested before Sahsen Ventures.
- Top Co-investors of Sahsen Ventures: 59 investors entered a company along with Sahsen Ventures. These include investors like Madrona (4 companies).
- Invested after Sahsen Ventures: A total of 39 investors have invested in Sahsen Ventures's portfolio after their investments. Top Investors include HHS (2 companies), Breakout Ventures (2 companies) and GSK (1 company).
Recent News related to Sahsen Ventures
•
Fred Hutch leaders raise $10M for new AI startup Synthesize Bio expedite drug discoveryGeekWire•Sep 17, 2025•Madrona, Science Direct, Synthesize Bio, Point Field Partners and 3 others
•
Health startup Archon Bio raises $20 million in fundingWebrazzi•Oct 31, 2024•Archon Bio, Madrona, DUMAC, Sahsen Ventures and 4 others
•
Archon emerges from stealth with $20M and ‘antibody cages’ to power up drug developmentTechCrunch+•Oct 30, 2024•Archon Bio, Madrona, DUMAC, Sahsen Ventures and 4 others
•
Halda Therapeutics Raises $126M in Series B Extension FinancingFinSMEs•Aug 12, 2024•Halda Therapeutics, Deep Track Capital, Frazier Life Sciences, RA Capital Management and 22 others
•
•
Insamo Launches with $12M Funding from Playground Global, venBio, and MRL Ventures Fund to Develop Best-in-Class Membrane-Permeable Macrocyclic PeptidesBusiness Wire•Feb 21, 2024•Insamo, Playground, VenBio, MRLV and 5 others
•
Parse Biosciences raises $50M for single cell sequencing techGeekWire•Dec 14, 2023•Parse Biosciences, Soleus Capital, Bioeconomy Capital, Janus Henderson Investors and 4 others
•
Monod Bio Closes $25M Seed FinancingMedical Product Outsourcing•Sep 19, 2022•Monod, Z47, Global Health Investment, Cercano Management and 4 others
•
Biotech Startup Monod Bio Collects $25 Million Seed FinancingThe Wall Street Journal•Aug 15, 2022•Monod, , Matrix Partners India, Global Health Investment and 6 others
•
Terray Therapeutics Raises $60M in Series A FundingFinSMEs•Feb 15, 2022•Terray, Madrona, Two Sigma Ventures, Digitalis Ventures and 6 others
